Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the target of unusually large options trading activity on Monday. Stock investors acquired 86,445 put options on the stock. This represents an increase of approximately 136% compared to the typical daily volume of 36,670 put options.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock traded up $0.12 during midday trading on Monday, reaching $13.58. 9,359,273 shares of the stock traded hands, compared to its average volume of 9,916,033. The stock has a market cap of $15.40 billion, a P/E ratio of -9.37, a PEG ratio of 1.44 and a beta of 0.72. The stock’s fifty day moving average is $15.79 and its 200-day moving average is $17.82. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of TEVA. Captrust Financial Advisors grew its holdings in shares of Teva Pharmaceutical Industries by 48.4% in the third quarter. Captrust Financial Advisors now owns 15,786 shares of the company’s stock worth $284,000 after purchasing an additional 5,146 shares during the last quarter. Quantinno Capital Management LP grew its stake in Teva Pharmaceutical Industries by 34.5% in the 3rd quarter. Quantinno Capital Management LP now owns 36,145 shares of the company’s stock worth $651,000 after acquiring an additional 9,269 shares in the last quarter. Stifel Financial Corp grew its stake in Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after acquiring an additional 23,283 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $198,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $3,732,000. 54.05% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TEVA shares. Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. Piper Sandler increased their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, StockNews.com upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Friday, April 4th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.